Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2000; 84(06): 1117-1118
DOI: 10.1055/s-0037-1614180
DOI: 10.1055/s-0037-1614180
Letters to the Editor
The FXIII Val 34 Leu Mutation and the Risk of Venous Thrombosis
Further Information
Publication History
Received
26 June 2000
Accpeted after revision
16 August 2000
Publication Date:
13 December 2017 (online)
-
References
- 1 Mikkola H, Syrjala M, Rasi V, Vahtera H, Hamalainen E, Peltonen L. Palotie A. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on novel transcript levels. Blood 1994; 84: 517-25.
- 2 Kohler HP, Stickland MH, Ossel-Gerning N, Carter A, Mikkola H, Grant P. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
- 3 Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-91.
- 4 Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII Val 34 Leu mutation. J Biol Chem. 2000 (in press).
- 5 Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93: 906-8.
- 6 Franco RF, Reitsma PH, Lourenco D, Maffei FH, Tavella MH, Araujo AG, Piccinato CE, Zago MA. Factor XIII Val34Leu is a genetic factor involved in the aetiology of venous thrombosis. Thromb Haemost 1999; 81: 676-9.
- 7 Corral J, Gonzalez-Conejero R, Iniesta JA, Rivea J, Martinez C, Vicente V. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica 2000; 85: 293-7.
- 8 Rosendaal FR, Grant PJ, Ariens RAS, Poort SR, Bertina RM. Factor XIII Val34Leu, factor XIII antigen and activity levels and risk of venous thrombosis. Thromb Haemost 1999; 82: 508-9 (Suppl., abstract 1599).
- 9 Arnaud E, Nicaud V, Poirier O, Rendu F, Alhenc-Gelas M, Fiessinger JN, Emmerich J, Aiach M. Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism. Arterioscler Thromb Vasc Biol 2000; 20: 585-92.
- 10 Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998; 92: 2766-70.
- 11 Cucherat M, Boissel JP, Leizorovicz A, Haugh MC, Easy MA. a program for the meta-analysis of clinical trials. Computer Methods and Programs in Biomedicine 1997; 53: 187-90.